Safety action
FDA adds rare optic nerve risk to warnings for all GLP-1 drugs
The FDA asked makers of GLP-1 receptor agonists to add NAION, a rare optic nerve disorder that can permanently impair sight, to label warnings. A pooled review of 126 trials found 10 possible cases on treatment and five on control, and causality remains unproven. Shares in Novo Nordisk and Eli Lilly climbed, as no boxed warning or prescribing limit was imposed.
Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.